The Supreme Court will hear an appeal by a coalition of 20 mainly Democratic states, which are hoping for a reversal of a Fifth Circuit Court of Appeals ruling that held the Affordable Care Act’s (ACA) individual mandate is unconstitutional and called into question whether the remaining provisions of the law could still stand. However, a decision will not come until after the November 2020 presidential election.
The Supreme Court agreed Monday to a hear an appeal by a coalition of 20 mainly Democratic states, which are hoping for a reversal of a Fifth Circuit Court of Appeals ruling, which held the Affordable Care Act’s individual mandate is unconstitutional and called into question whether the remaining provisions of the law could still stand.
Among those provisions, of course, are the Biologics Price Competition and Innovation Act (BPCIA). The Department of Justice had argued that the Fifth Circuit should not only affirm that decision, but it should further find that other ACA provisions should also be struck down if the individual mandate was not severable from the rest of the statute.
Any effect on the BPCIA will hinge on the question of severability, observers have said.
In a statement, AARP’s Nancy LeaMond, executive vice president and chief advocacy and engagement officer praised the decision to review the case, Texas v Azar.
“We urge the Court to uphold the ACA by overturning the lower appellate court’s decision,” she said. "A final ruling by the Supreme Court is needed to end years of uncertainty for millions of Americans who worry that they will lose access to critical health care coverage and essential consumer protections. It would also end the uncertainty for insurers and state and local governments who must make advance decisions each year about participating in the ACA Marketplaces and other ACA programs.”
However, a decision in the case will not come until after the November 2020 presidential election. The new term for the court does not begin until October.
There are no changes to the ACA while the case continues.
California Attorney General Xavier Becerra, leading a coalition of 20 states and Washington DC, applauded the high court’s decision. In a statement, his office said it urged the court to take up the case to “resolve the uncertainty created by the Fifth Circuit decision, which threatens the health of millions of Americans, as well as doctors, clinics, and the healthcare market.”
At issue is whether the other parts of the law can survive without the mandate; the Republican-led states, led by Texas, said that when the tax penalty was eliminated under President Donald Trump's 2017 tax cut package, it also made the ACA unconstitutional. Democratic states opposed the challenge, saying that reducing the tax penalty to zero did not eliminate the requirement.
“The Fifth Circuit correctly applied existing US Supreme Court precedent when they ruled that the individual mandate itself was unconstitutional, said Texas Attorney General Ken Paxton in a statement. “Without the individual mandate, the entire law becomes unsupportable. The federal government cannot order private citizens to purchase subpar insurance that they don’t want, and I look forward to finally settling the matter before the US Supreme Court.”
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
August 21st 2024Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.
Eye on Pharma: VA Picks Hadlima; Biocon, Sandoz Partnership; A Stelara Settlement Abroad
February 21st 2024The US Department of Veterans Affairs (VA) has chosen to replace Humira (adalimumab) with Organon’s biosimilar version on its national formulary; Biocon Biologics and Sandoz announce a new partnership in Australia for 2 biosimilars; Alvotech settles with Johnson & Johnson over its biosimilar to Stelara (ustekinumab) for the European and Canadian markets.